Lineage’s COR1 targets restoration of endothelial pump function via intracameral delivery and adhesion to Descemet membrane, ...

In unilateral intermittent exotropia, distance control improved significantly over 3 months of therapy (mean 2.9 to 1.7; ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...

In this episode of “iOpeners” from Ophthalmology Times, host Nicole Bajic, MD, comprehensive ophthalmologist at the Cole Eye Institute, Cleveland Clinic, speaks with Emily Schehlein, MD, about efforts ...

BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...

Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...

What it is. AXPAXLI (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel implant designed to continuously ...

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

Their Perspective article, published in npj Digital Medicine, warns that treating medical artificial intelligence (AI) as an ...